After Today’s Huge Increase, Is Fortress Biotech, Inc. (FBIO)’s Near-Term Analysis Positive?

March 14, 2018 - By Hazel Jackson

The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) is a huge mover today! The stock increased 0.75% or $0.04 during the last trading session, reaching $5.35. About 345,570 shares traded or 122.15% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since March 14, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.
The move comes after 6 months positive chart setup for the $271.01 million company. It was reported on Mar, 14 by We have $5.78 PT which if reached, will make NASDAQ:FBIO worth $21.68M more.

Analysts await Fortress Biotech, Inc. (NASDAQ:FBIO) to report earnings on March, 15. They expect $-0.57 earnings per share, down 32.56 % or $0.14 from last year’s $-0.43 per share. After $-0.67 actual earnings per share reported by Fortress Biotech, Inc. for the previous quarter, Wall Street now forecasts -14.93 % EPS growth.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 3 analysts covering Fortress Biotech (NASDAQ:FBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 8 analyst reports since July 11, 2017 according to SRatingsIntel. H.C. Wainwright maintained Fortress Biotech, Inc. (NASDAQ:FBIO) rating on Tuesday, December 12. H.C. Wainwright has “Buy” rating and $11.0 target. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Tuesday, July 11 by H.C. Wainwright. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Wednesday, September 27 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, December 5 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 2. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Thursday, August 10 by H.C. Wainwright.

More news for Fortress Biotech, Inc. (NASDAQ:FBIO) were recently published by:, which released: “Mustang Bio to Present at the 255th American Chemical Society National Meeting …” on March 12, 2018.‘s article titled: “Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research …” and published on February 26, 2018 is yet another important article.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $271.01 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: